MX2020000086A - Metodo para predecir y monitorear una respuesta clinica a una terapia inmunomoduladora. - Google Patents

Metodo para predecir y monitorear una respuesta clinica a una terapia inmunomoduladora.

Info

Publication number
MX2020000086A
MX2020000086A MX2020000086A MX2020000086A MX2020000086A MX 2020000086 A MX2020000086 A MX 2020000086A MX 2020000086 A MX2020000086 A MX 2020000086A MX 2020000086 A MX2020000086 A MX 2020000086A MX 2020000086 A MX2020000086 A MX 2020000086A
Authority
MX
Mexico
Prior art keywords
immune
determination
predicting
immunosuppressant
clinicians
Prior art date
Application number
MX2020000086A
Other languages
English (en)
Inventor
De Las Herrerías Javier Dotor
Scala Marianna Di
Verónica Sánchez
Sánchez Isabel Portero
Original Assignee
Biohope Scient Solutions For Human Health S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP17382399.8A external-priority patent/EP3421994B1/en
Application filed by Biohope Scient Solutions For Human Health S L filed Critical Biohope Scient Solutions For Human Health S L
Publication of MX2020000086A publication Critical patent/MX2020000086A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/50—Proteins
    • C12N2533/54—Collagen; Gelatin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/70—Polysaccharides
    • C12N2533/76—Agarose, agar-agar
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G01N2800/245—Transplantation related diseases, e.g. graft versus host disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • General Engineering & Computer Science (AREA)

Abstract

La presente invención proporciona un método para medir cuantitativamente la respuesta de un paciente a un fármaco inmunomodulador que ayudará a los médicos clínicos en la determinación de la combinación/posología óptima de los fármacos inmunosupresores/inmunomoduladores. Además, este método abrirá la posibilidad para que los médicos clínicos realicen los ajustes necesarios en la terapia inmunosupresora, como una forma de evitar que tenga lugar efectivamente el rechazo de órganos. Además, este método reducirá significativamente los efectos secundarios de los fármacos inmunosupresores, optimizar el esquema terapéutico y las dosificaciones, permitiendo la determinación del régimen de inmunosupresión más efectivo a las dosificaciones más bajas para cada paciente individualmente y monitorear la eficacia del tratamiento a lo largo del tiempo, abriendo con esto la puerta a la personalización del tratamiento.
MX2020000086A 2017-06-26 2018-06-26 Metodo para predecir y monitorear una respuesta clinica a una terapia inmunomoduladora. MX2020000086A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17382399.8A EP3421994B1 (en) 2017-06-26 2017-06-26 Method for predicting and monitoring clinical response to immunomodulatory therapy
EP17382923 2017-12-29
PCT/EP2018/067137 WO2019002305A1 (en) 2017-06-26 2018-06-26 METHOD OF PREDICTING AND MONITORING CLINICAL RESPONSE TO IMMUNOMODULATORY THERAPY

Publications (1)

Publication Number Publication Date
MX2020000086A true MX2020000086A (es) 2020-08-06

Family

ID=62636230

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020000086A MX2020000086A (es) 2017-06-26 2018-06-26 Metodo para predecir y monitorear una respuesta clinica a una terapia inmunomoduladora.

Country Status (7)

Country Link
US (2) US11175282B2 (es)
EP (1) EP3646026A1 (es)
KR (1) KR102571917B1 (es)
BR (1) BR112019027773A2 (es)
CA (1) CA3068364C (es)
MX (1) MX2020000086A (es)
WO (1) WO2019002305A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020000086A (es) * 2017-06-26 2020-08-06 Biohope Scient Solutions For Human Health S L Metodo para predecir y monitorear una respuesta clinica a una terapia inmunomoduladora.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2634119C (en) * 2005-12-21 2015-02-24 Vaxdesign Corporation A porous membrane device that promotes the differentiation of monocytes into dendritic cells
US9097702B2 (en) * 2008-07-29 2015-08-04 Cornell University Pathologically relevant tumor microenvironments for high-throughput drug screening
WO2011078990A1 (en) 2009-12-14 2011-06-30 Benaroya Research Institute At Virginia Mason Hydrogels comprising hyaluronan and at least one t cell induction agent
WO2013025543A1 (en) * 2011-08-12 2013-02-21 Solidus Biosciences, Inc. Cell chips
KR101592305B1 (ko) * 2013-10-08 2016-02-05 사회복지법인 삼성생명공익재단 한계희석법을 이용한 환자 맞춤형 항암제의 스크리닝 방법
DE102014104566B4 (de) * 2014-04-01 2016-06-02 Leibniz-Institut Für Polymerforschung Dresden E.V. Physikalisches selbstorganisierendes Hydrogelsystem für biotechnologische Anwendungen
MX2020000086A (es) * 2017-06-26 2020-08-06 Biohope Scient Solutions For Human Health S L Metodo para predecir y monitorear una respuesta clinica a una terapia inmunomoduladora.

Also Published As

Publication number Publication date
US20220283143A1 (en) 2022-09-08
KR20200019746A (ko) 2020-02-24
KR102571917B1 (ko) 2023-08-28
CA3068364C (en) 2023-09-26
CA3068364A1 (en) 2019-01-03
US20180372723A1 (en) 2018-12-27
WO2019002305A1 (en) 2019-01-03
BR112019027773A2 (pt) 2020-07-07
US11175282B2 (en) 2021-11-16
EP3646026A1 (en) 2020-05-06

Similar Documents

Publication Publication Date Title
MX2020008882A (es) Dosificación para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1.
MX2018002723A (es) Macrociclicos peptidomimeticos y usos de los mismos.
MX2023002251A (es) Antagonistas de union al eje pd-l1 y usos de los mismos para el tratamiento de cancer.
WO2019094692A3 (en) Extracellular vesicle proteins and their use for cancer diagnosis, predicting response to therapy, and treatment
EA201792642A1 (ru) Способы диагностики для т-клеточной терапии
EP3064509A3 (en) Anti-angiogenesis therapy for the treatment of ovarian cancer
MX2019011148A (es) Metodos de tratamiento.
MX2017003819A (es) Macrociclos peptidomimeticos y formulaciones de los mismos.
BR112019007844A2 (pt) tratamento de câncer gástrico usando terapias de combinação compreendendo irinotecano lipossômico, oxaliplatina, 5-fluoroacila (e leucovorina)
MY189857A (en) Methods of selecting t cell line and donor thereof for adoptive cellular therapy
MX2018007669A (es) Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert.
PH12014502507A1 (en) Anti-angiogenesis therapy for the treatment of breast cancer
MX2018008709A (es) Uso terapeutico de inhibidores de activacion o estimulacion de celulas t.
WO2017062456A3 (en) Biomarkers related to interleukin-33 (il-33)-mediated diseases and uses thereof
MX2011013775A (es) Un metodo para el tratamiento, alivio de sitomas de, mitigacion, mejoramieto y prevencion de una enfermedad, desorden o condicion cognoscitiva.
MX2017004133A (es) Electrodo, dispositivo y metodo para la estimulacion electrica cerebral profunda.
MX2017003513A (es) Formación de imágenes de inflamación e infección dirigida a hsp90 y terapia.
MX2022000107A (es) Metodos de tratamiento que tienen toxicidad relacionada con farmacos reducida y metodos para identificar la probabilidad de da?o que surja de medicamentos recetados a pacientes.
MX2017003406A (es) Metodo para tratar enfermedades de metastasis osea, medicamentos para las mismas, y metodo para predecir el resultado clinico para tratar enfermedades de metastasis osea.
WO2017069288A8 (en) Pharmaceutical composition for use in treating aml and method of treating aml in a subject in need thereof
MX2020000086A (es) Metodo para predecir y monitorear una respuesta clinica a una terapia inmunomoduladora.
WO2013106766A3 (en) THERAPEUTIC INDICATIONS OF miR-1291
MX2018009499A (es) Anticuerpos monoclonales especificos de egfl6 y metodos de su uso.
MX2020006660A (es) Biomarcadores de tolerancia inmunitaria inducida por metotrexato.
IL281920A (en) Methods for the treatment of peripheral T-cell lymphoma using anti-CD30 antibody drug conjugate therapy